British Journal of Clinical Pharmacology 2007: Vol 64 Index & Table of Contents

2007·5.8 MB·English

British Journal of Clinical Pharmacology |
AUTHOR INDEX
ABDULLA, A. see MILTON, J.C. BECKWITH, S. FRANKLIN, P. & BOURAOUI, K. see HMOUDA, H.
ACS, N. see BANHIDY, F. LEATHARD, H. Oxford Handbook of BOURAOUI, K. see SALEM, C.B.
ADAMSKA, K. see WYKRETOWICZ, A. Nurse Prescribing: 115 BOURGAREL-REY, V. see SOLAS, C.
AIRAKSINEN, M.S. see BELL, J.S. BEGAUD, B. see ARIMONE, Y. BOUW, MLR. see PESCOVITZ, M.D.
AKHTAR, S. see MISHRA, B. BEGG, E.J. see ARONSON, J.K. BOZKURT, S. see UNVERIR, P.
AKHTAR, S. see SAHOO, S. BEIJNEN, J.H. see JOERGER, M. BRADSHAW, C.M. see SAMUELS, E.R.
ALAMARTINE, E. see BERGES, A. BELL, J.S., AIRAKSINEN, M.S., LYLES, BRAMNESS, J.G., FURU, K., ENGELAND,
ALCELIK, A. see CINEMRE, H. A., CHEN, T.F. & ASLANI, P. A. & SKURTVEIT, S. Carisoprodol use
ANDERSSON, T. see SOSTEK, M.B. Concordance is not synonymous with and abuse in Norway. A
ANTIGNAC, M., BARROU, B.., compliance or adherence: 710 pharmacoepidemiological study: 210
FARINOTTI, R., LECHAT, P. & URIEN, BELOEIL, H., EURIN, M., THEVENIN, A.. BRAUNSTEIN, R. see GOLDSTEIN, L.H.
S. Population pharmacokinetics and BENHAMOU, D. & MAZOIT, J.-X. BRENDEL, K. see DARTOIS, C.
bioavailability of tacrolimus in kidney Effective dose of nefopam in 80% of BRETTMAN, L.R. see MOULD, D.R.
transplant patients: 750 patients (EDgo): a study using the BRUN, A. see THUNELL, S.
ARIMONE, Y., MIREMONT-SALAME, G., continual reassessment method: 686 BRUNET, C. see SOLAS, C.
HARAMBURU, F., MOLIMARD, M., BENETON, M., CHAPET, S., BLASCO, H., BUCLIN, T. see TSCHUPPERT, Y.
MOORE, N., FOURRIER-REGLAT, A. GIRAUDEAU, B., BOISDRON-CELLE, BUHRMANN, S. see STASS, H.
& BEGAUD, B. Inter-expert agreement M., DEPORTE-FETY, R., DENIS, F., BURGGRAAF, J. see VAN DER VORST,
of seven criteria in causality assessment NARCISSO, B., CALAIS, G. & LE M.M.J.
of adverse drug reactions: 482 GUELLEC, C. Relationship between
ARONSON, J.K. An agenda for research on 5-fluorouracil exposure and outcome in CAI, Z.-J. see TANG, Y.-L.
adverse drug reactions: 119 patients receiving continuous venous CALAIS, G. see BENETON, M.
ARONSON, J.K. Old drugs — new uses: 563 infusion with or without concomitant CALLEJA, E. see PESCOVITZ, M.D.
ARONSON, J.K. Plagiarism — please don’t radiotherapy: 613 CALS, L. see MAGNE, N.
copy: 403 BENHAMOU, D. see BELOEIL, H. CALVO, L. see MORENO, R.
ARONSON, J.K. Time to abandon the term BENNETT, K. see KABIR, Z. CENACCHI, V. see CIVELLI, M.
‘patient concordance’: 711 BENNETT, K. see MAHMUD, A. CHACHTER, M.S. see ARONSON, J.K.
ARONSON, J.K., COHEN, A., RITTER, BENNETT, K. see OKRECHUKWU, I. CHAPET, S. see BENETON, M.
J.M., BEGG, E.J., LEWIS, L.D. & BENNETT, K. see TEELING, M. CHAPPUY, H. see HIRT, D.
CHACHTER, M.S. Editors’ Report for BERARD, A. see OFORI, B. CHEN, B.-L. see ZHANG, W.
2006: 253 BERGES, A., LAPORTE, S., EPINAT, M.., CHEN, Q. see TANG, Y.-L.
ASARI, A., ILES-SMITH, H., CHEN, Y.-C., ZUFFEREY, P., ALAMARTINE, E., CHEN, T.F. see BELL, J.S.
NADERER, O.J., JOHNSON, M.A., TRANCHAND, B., DECOUSUS, H., & CHEN, W. see PEREZ-RUIXO, J.J.
YUEN, G.J., OTTO, V., DUNN, J.A. & MISMETTI, P. Anti-factor Xa activity of CHEN, X. see ZHANG, Y.
GOKAL, R. Pharmacokinetics of enoxaparin administered at prophylactic CHEN, Y. see SOSTEK, M.B.
lamivudine in subjects receiving dosage to patients over 75 years old: 428 CHEN, Y.-C. see ASARI, A.
peritoneal dialysis in end-stage renal BERKOVITCH, M. see GOLDSTEIN, L.H. CHOI, J.H., LEE, Y.J., JANG, S$.B., LEE,
failure: 738 BERLIN, R.G. see DESJARDINS, P.J. J.-E., KIM, K.H. & PARK, K. Influence
ASLANI, P. see BELL, J.S. BINIAURISHVILI, B.Z. see GOLDSTEIN, of the CYP3A5 and MDRI genetic
ASLANI, P. see MAI, A. LH. polymorphisms on the pharmacokinetics
ATTHOBARI, J.. GANSEVOORT, R.T., BIOLLAZ, J. see TSCHUPPERT, Y. of tacrolimus in healthy Korean subjects:
VISSER, S.T., DE JONG, P.E. & DE BIRKETT, D.J. see ELLIOT, D.J. 185
JONG-VAN DEN BERG, L.T.W. The BISGAARD, H. see BONNELYKKE, K. CHOW, A. see PEREZ-RUIXO, J.J.
effect of screening for cardio-renal risk BLANCHE, S. see JULLIEN, V. CHURCH, R., TANSEY, T., & COHEN, A.
factors on drug use in the general BLASCO, H. see BENETON, M. Burroughs Wellcome & Co. Knowledge,
population: 810 BOCKARIE, M.J. see MEHLOTRA, R.K. Trust, Profit and the Transformation of
BOISDRON-CELLE, M. see BENETON, M. the British Pharmaceutical Industry,
BACKMAN, J.T. see FANTA, S. BONATE, P.L. see MOULD, D.R. 1880-1940: 562
BAE, K.S. see KANG, S.H. BONGARD, V. see DURRIEU, G. CINEMRE, H., KORKMAZ, U., ALCELIK,
BANFIELD, C. see GUPTA, S.K. BONNELYKKE, K., JESPERSEN, J.J. & A., ONDER, E. & GUNGOR, A. Safety
BANGS, MLE. see CUI, Y.M. BISGAARD, H. Age dependent systemic of amlodipine use in patients with acute
BANHIDY, F., ACS, N., PUHO, E. & exposure to inhaled salbutamol: 241 intermittent porphyria: 246
CZEIZEL, A.E. Ergotamine treatment BONOVAS, S., FILIOUSSI, K., TSANTES, CIVELLI, M., PRETI, A.P.M., CENACCHI,
during pregnancy and a higher rate of low A. & SITARAS, N.M. Use of statins and V., RONDELLI, I., GUASTALLA, D.,
birthweight and preterm birth: 510 risk of haematological malignancies: a TARRAL, A., DOSTERT, P.,
BARROU, B. see ANTIGNAC, M. meta-analysis of six randomized clinical GUILLEVIC, Y. & HOMERY, M.-C.
BATEMANI] , D.N. see PAKRAVAN, N. trials and eight observational studies: 255 Single and multiple ascending dose
BAUMAN, J.N. see PETERKIN, V.C. BOUILLON-PICHAULT, M. see studies of a novel tissue-selective
BAUMANN, A. see MOULD, D.R. JULLIEN, V. oestrogen receptor modulator, CHF
© 2007 Blackwell Publishing Ltd Br J Clin Pharmacol 64:6 835-841 835
| Author Index
4227, in healthy postmenopausal women: DELAUGERRE, C. see JULLIEN, V. P450 catalysing the rate-limiting
304 DEN HARTIGH, J. see VAN DER VORST, pathways of gliclazide elimination:
COHEN, A. see ARONSON, J.K. M.M.J. 450
COHEN, A. see CHURCH, R. DENG, S. see ZHANG, W. ELLIOTT, K. see STEWART, D.
COHEN, A. Should we tolerate tolerability as DENIS, F. see BENETON, M. ENGELAND, A. see BRAMNESS, J.G.
an objective in early drug development?: DEPORTE-FETY, R. see BENETON, M. EPINAT, M. see BERGES, A.
249 DEPRE, M. see VAN DER SCHUEREN, ERNST, E. A re-evaluation of kava (Piper
COHEN, A.F. see VAN DER VORST, B.J. methysticum): 415
M.M.J. DESJARDINS, P.J. & BERLIN, R.G. ESPOSITO-FESTEN, J.E., ZANEN, P.,
COMETS, E. see DARTOIS, C. Efficacy of phenylephrine: 555 TIDDENS, H.A.W.M. & LAMMERS,
CONIL, J.M., GEORGES, B., LAVIT, M., DHAUN, N., MELVILLE, V., KRAMER, J.-W.J. Pharmacokinetics of inhaled
LAGUERRE, J., SAMII, K., HOUIN, G. W., STAVROS, F., COYNE, T., SWAN, monodisperse beclomethasone as a
& SAIVIN, S. A population S., GODDARD, J. & WEBB, D.J. The function of particle size: 328
pharmacokinetic approach to ceftazidime pharmacokinetic profile of sitaxsentan, a ETIENNE-GRIMALDI, M.-C. see
use in burn patients: influence of selective endothelin receptor antagonist, MAGNE, N.
glomerular filtration, gender and in varying degrees of renal impairment: EURIN, M. see BELOEIL, H.
mechanical ventilation: 27 733 EVANS, A.M. see FORNASINI, G.
COYNE, T. see DHAUN, N. DICKINSON, G.L., LENNARD, M.S., EZATAGHA, A. see SIEVENPIPER, J.L.
CUI, Y.M., TENG, C.H., PAN, A.X., TUCKER, G.T. &
YUEN, E., YEO, K.P., ZHOU, Y., ROSTAMI-HODJEGAN, A. The use of FAN, L. see ZHANG, W.
ZHAO, X., LONG, A.J., BANGS, M.E. mechanistic DM-PK-PD modelling to FANTA, S., JONSSON, S., BACKMAN,
& WISE, S.D. Atomoxetine assess the power of pharmacogenetic J.T., KARLSSON, M.O. & HOPPU, K.
pharmacokinetics in healthy Chinese studies — CYP2C9 and warfarin as an Developmental pharmacokinetics of
subjects and effect of the CYP2D6*10 example: 14 ciclosporin — a population
allele: 445 DIMET, J. see JULLIEN, V. pharmacokinetic study in paediatric renal
CULLEN, G. see DONNELLAN, F. DOBRE, D., VAN VELDHUISEN, D.J., transplant candidates: 772
CUTLER, D.L. see GUPTA, S.K. DEJONGSTE, M.J.L., VAN FARDON, T.C. see TAYAB, Z.R.
CZEIZEL, A.E. see BANHIDY, F. SONDEREN, E., KLUNGEL, O.H., FARINOTTI, R. see ANTIGNAC, M.
SANDERMAN, R., RANCHOR, A.V. & FAVA, S. see FRENDO, M.
DAILLY, E. see VICTORRI-VIGNEAU, C. HAAIJER-RUSKAMP, F.M. The FEELY, J. see KABIR, Z.
DAMASE-MICHEL, C. see DURRIEU, G. contribution of observational studies to FEELY, J. see MAHMUD, A.
DARLINGTON, L.G. see FORREST, C.M. the knowledge of drug effectiveness in FEELY, J. see OKECHUKWJU, I.
DARTOIS, C., BRENDEL, K., COMETS, heart failure: 406 FEELY, J. see TEELING, M.
E., LAFFONT, C.M., LAVEILLE, C., DOESSEGGER, L. see THAKRAR, B.T. FERNANDEZ, C. see MORENO, R.
TRANCHAND, B., MENTRE, F., DONNELLAN, F., CULLEN, G., FILIOUSSI, K. see BONOVAS, S.
LEMENUEL-DIOT, A. & GIRARD, P. HEGARTY, J.E. & MCCORMICK, P.A. FIRTION, G. see HIRT, D.
Overview of model-building strategies in Ischaemic complications of Glypressin in FISHER, P. see MATHIE, R.T.
population PK/PD analyses: 2002-2004 liver disease: a case series: 550 FORCONI, S. see GORI, T.
literature survey: 603 DOSTERT, P. see CIVELLI, M. FORMENTO, J.-L. see MAGNE, N.
DASCALU, A. see SIEVENPIPER, J.L. DRAGONI, S. see GORI, T. FORNASINI, G., UPTON, R.N. & EVANS,
DE BOER, A. see GUMBS, P.D. DREWE1 , J. see HAEGELI, L. A.M. A pharmacokinetic model for
DE BOER, A. see SCHELLEMAN, H. DROGOUL, M.-P. see SOLAS, C. L-carnitine in patients receiving
DE DONCKER, P. see HOETELMANS, DRUMMOND, P.D. Repeated cycles of haemodialysis: 335
R.M.W. electrical stimulation decrease FORREST, C.M., MACKAY, G.M., STOY,
DE GRAEFF, A. see JOERGER, M. vasoconstriction and axon-reflex N., STONE, T.W. & DARLINGTON,
DE GROOT, M.C.H. & VAN vasodilation to noradrenaline in the L.G. Inflammatory status and kynurenine
PUIJENBROEK, E.P. Clindamycin and human forearm: 421 metabolism in rheumatoid arthritis treated
taste disorders: 542 DUNN, J.A. see ASARI, A. with melatonin: 517
DE GROOT, M.C.H. see HARMARK, L. DURAND, A. see SOLAS, C. FORST, T., SMITH, T., SCHUTTE, K.,
DE HOON, J.N. see VAN DER DURRIEU, G., HURAULT, C., BONGARD, MARCUS, P. & PFUTZNER, A. Dose
SCHUEREN, B.J. V., DAMASE-MICHEL, C. & escalating safety study of CNS 5161 HCl,
DE JONG, P.E. see ATTHOBARI, J. MONTASTRUC, J.L. Perception of risk a new neuronal glutamate receptor
DE JONG-VAN DEN BERG, L.T.W. see of adverse drug reactions by medical antagonist (NMDA) for the treatment of
ATTHOBARI, J. students: influence of a | year neuropathic pain: 75
DE LEPELEIRE, I. see VAN DER pharmacological course: 233 FOURRIER-REGLAT, A. see ARIMONE, Y.
SCHUEREN, B.J. FRANCOUAL, M. see MAGNE, N.
DE PAUW, M. see HOETELMANS, R.M.W. EARL, J.W. see NATH, C.E. FRANKLIN, P. see BECKWITH, S.
DE WIT, G.A. see GUMBS, P.D. ECCLES, R. Efficacy of phenylephrine: FRENDO, M., THEUMA, R. & FAVA, S.
DEAR, J.W. & WEBB, D.J. Disease 557 Delayed bezafibrate-induced
mongering — a challenge for everyone ELIAS, M. see GOLDSTEIN, L.H. angio-oedema in a 68-year-old man:
involved in healthcare: 122 ELLIOT, D.J., SUHARJONO, LEWIS, B.C., 560
DECOSTERD, L.A. see TSCHUPPERT, Y. GILLAM, E.M.J., BIRKETT, D.J., FRIXON-MARIN, V. see SOLAS, C.
DECOUSUS, H. see BERGES, A. GROSS, A.S. & MINERS, J.O. FURU, K. see BRAMNESS, J.G.
DEJONGSTE, M.J.L. see DOBRE, D. Identification of the human cytochromes FURU, K. see SAKSHAUG, S.
836 64:6 Br J Clin Pharmacol
Se eg ae ee a
GALEOTE, G. see MORENO, R. GUPTA, S.K., SWAN, S.K., MARBURY, T., HOWELL, C., WILSON, A.D. & WARING,
GALLEYRAND, J. see TSCHUPPERT, Y. SMITH, W., SCHWARTZ, S., KOLZ, K. W.S. Cardiovascular toxicity due to
GANSEVOORT, R.T. see ATTHOBARI, J. & CUTLER, D.L. Multiple-dose venlafaxine poisoning in adults: a review
GANSSER, D. see STANGIER, J. pharmacokinetics of peginterferon of 235 consecutive cases: 192
GASTAUT, J.-A. see SOLAS, C. alfa-2b in patients with renal HUGHES, J., LOCKHART, J. & JOYCE, A.
GAUD, C. see TSCHUPPERT, Y. insufficiency: 726 Do calcium antagonists contribute to
GEORGES, B. see CONIL, J.M. GUZIK, P. see WYKRETOWICZ, A. gastro-oesophageal reflux disease and
GIBBINS, J.M. see GUERRERO, J.A. concomitant noncardiac chest pain?: 83
GILBERT, A.L. see ROUGHEAD, E.E. HAAIJER-RUSKAMP, F.M. see DOBRE, D. HUITEMA, A.D.R. see JOERGER, M.
GILLAM, E.M.J. see ELLIOT, D.J. HAEGELI, L., ROCCA, H.P.B.-L., WENK, HUIZING, M.T. see JOERGER, M.
GIRARD, P. see DARTOIS, C. M., PFISTERER, M., DREWE1, J. & HURAULT, C. see DURRIEU, G.
GIRAUDEAU, B. see BENETON, M. KRAHENBUHL, S. Sublingual
GODDARD, J. see DHAUN, N. administration of furosemide: new ILES-SMITH, H. see ASARI, A.
GODDARD, J. see PAKRAVAN, N. application of an old drug: 804 IWASHIMA, K., YASUI-FURUKORI, N.,
GOKAL, R. see ASARI, A. HAGGART, K. see TAYAB, Z.R. KANEDA, A., SAITO, M., NAKAGAMI,
GOLDSTEIN, L.H., ELIAS, M., HARAMBURJU, F. see ARIMONE, Y. T., SATO, Y. & KANEKO, S. No
RON-AVRAHAM, G., HARMARK, L., VAN DER WIEL, H.E., DE association between CYP2D6
BINIAURISHVILI, B.Z., MADJAR, M., GROOT, M.C.H. & VAN polymorphisms and personality trait in
KAMARGASH, I., BRAUNSTEIN, R., GROOTHEEST, A.C. Proton pump Japanese: 96
BERKOVITCH, M. & GOLIK, A. inhibitor-induced acute interstitial
Consumption of herbal remedies and nephritis: 819 JANG, S.B. see CHOI, J.H.
dietary supplements amongst patients HARRISON, T.W. see MORTIMER, K.J. JESPERSEN, J.J. see BONNELYKKE, K.
hospitalized in medical wards: 373 HART, M. see PESCOVITZ, M.D. JIANG, F. see TANG, Y.-L.
GOLIK, A. see GOLDSTEIN, L.H. HAYES, S. see PEREZ-RUIXO, J.J. JICK, H. see JICK, S.S.
GOOSEN, T.C. see PETERKIN, V.C. HE, Y.-J. see ZHANG, W. JICK, S.S., KAYE, J.A. & JICK, H.
GORI, T., STOLFO, G.D., SICURO, S.., HEGARTY, J.E. see DONNELLAN, F. Diclofenac and acute myocardial
DRAGONI, S., LISI, M., FORCONI, S. HELMS, P.J. see STEWART, D. infarction in patients with no major risk
& PARKER, J.D. Nitroglycerin protects HENDERSON, L. see RICHARDSON, W.N. factors: 662
the endothelium from ischaemia and HILL, A. see HOETELMANS, R.M.W. JOERGER, M., HUITEMA, A.D.R.,
reperfusion: human mechanistic insight: HILLMEN, P. see MOULD, D.R. HUIZING, M.T., WILLEMSE, P.H.B..,
145 HIRT, D., URIEN, S., JULLIEN, V., DE GRAEFF, A., ROSING, H.,
GRAAH. seNe KEARLSNSON,, K .E. FIRTION, G., CHAPPUY, H., REY, E., SCHELLENS, J.H.M., BEIJNEN, J.H. &
GRAHA. sNeeE LONNNEB,O, A. PONS, G., MANDELBROT, L. & VERMORKEN, J.B. Safety and
GRIRA, M. see HMOUDA, H. TRELUYER, J.-M. Pharmacokinetic pharmacology of paclitaxel in patients
GROSS, A.S. see ELLIOT, D.J. modelling of the placental transfer of with impaired liver function: a population
GRUNDSCHOBER, S.B. see THAKRAR, nelfinavir and its M8 metabolite: a pharmacokinetic-pharmacodynamic
B.T. population study using 75 maternal-cord study: 622
GUASTALLA, D. see CIVELLI, M. plasma samples: 634 JOHNSON, M.A. see ASARI, A.
GUERRERO, J.A., NAVARRO-NUNEZ, L.. HMOUDA, H. see SALEM, C.B. JOLLIET, P. see VICTORRI-VIGNEAU, C.
LOZANO, M.L., MARTINEZ, C., HMOUDA, H., SALEM, C.B., GRIRA, M., JONSSON, E.N. see KARLSSON, K.E.
VICENTE, V., GIBBINS, J.M. & SLIM, R. & BOURAOUI, K. JONSS.S seOe FNANT,A, S.
RIVERA, J. Flavonoids inhibit the Carbamazepine-induced urinary retention: JOYCE, A. see HUGHES, J.
platelet TxA2 signalling pathway and 833 JULLIEN, V. see HIRT, D.
antagonize TxA2 receptors (TP) in HOCHHAUS, G. see MORTIMER, K.J. JULLIEN, V., RAIS, A., URIEN, S., DIMET,
platelets and smooth muscle cells: HOCHHAUS, G. see TAYAB, Z.R. J., DELAUGERRE, C.,
133 HOELEN, D.W.M., TJAN, D.H.T., VAN BOUILLON-PICHAULT, M., REY, E.,
GUILLEVIC, Y. see CIVELLI, M. VUGT, R., VAN DER MEER, Y.G. & PONS, G., BLANCHE, S. &
GUMBS, P.D., VERSCHUREN, W.M.M.., VAN ZANTEN, A.R.H. Severe local TRELUYER, J.M. Age-related
SOUVEREIN, P.C., vancomycin induced skin necrosis: differences in the pharmacokinetics of
MANTEL-TEEUWISSE, A.K., DE WIT, 553 stavudine in 272 children from birth
G.A., DE BOER, A. & KLUNGEL, O.H. HOETELMANS, R.M.W., MARIEN, K., DE to 16 years: a population analysis:
Society already achieves economic PAUW, M., HILL, A., PEETERS, M.., 105
benefits from generic substitution but fails SEKAR, V., DE DONCKER, P., JUNG, H.-E. see KIM, H.-S.
to do the same for therapeutic WOODFALL, B. & LEFEBVRE, E.
substitution: 680 Pharmacokinetic interaction between KABIR, Z., FEELY, J. & BENNETT, K.
GUNALE, B.K. see SUBBANNA, P.K. TMC114/ritonavir and tenofovir Primary care prescribing patterns in
GUNGOR, A. see CINEMRE, H. disoproxil fumarate in healthy volunteers: Ireland after the publication of large
GUO, Y. see ZHANG, Y. 655 hypertension trials: 381
GUPTA, S.K., KANTESARIA, B.., HOFMAN, A. see SCHELLEMAN, H. KAMARGASH, I. see GOLDSTEIN, L.H.
BANFIELD, C. & WANG, Z. HOMERY, M.-C. see CIVELLI, M. KANE, S.A. see VAN DER SCHUEREN,
Desloratadine dose selection in children HOPPU, K. see FANTA, S. B.J.
aged 6 months to 2 years: comparison of HOU, R.H. see SAMUELS, E.R. KANEDA, A. see IWASHIMA, K.
population pharmacokinetics between HOUGHTON, P. see WIART, C. KANEKO, S. see IWASHIMA, K.
children and adults: 174 HOUIN, G. see CONIL, J.M. KANG, H.-J. see KIM, H.-S.
Br J Clin Pharmacol 64:6 837
| Author Index
KANG, S.H., POYNTON, M.R., KIM, K.M., LECKRIDGE, R. Scottish GPs use of chronic atrial fibrillation identified from
LEE, H., KIM, D.H., LEE, S.H., BAE, homeopathy: 397 digoxin prescribing: 706
K.S., LINARES, O., KERN, S.E. & LEE, D.K.C. see TAYAB, Z.R. MAI, A. & ASLANI, P. Impact of
NOH, G.J. Population pharmacokinetic LEE, H. see KANG, S.H. Vietnamese written and verbal medicine
and pharmacodynamic models of LEE, J.-E. see CHOI, J.H. information on Vietnamese-speaking
remifentanil in healthy volunteers using LEE, S.H. see KANG, S.H. Australians’ knowledge and satisfaction:
artificial neural network analysis: 3 LEE, Y.J. see CHOI, J.H. 527
KANTESARIA, B. see GUPTA, S.K. LEFEBVRE, E. see HOETELMANS, R.M.W. MAN, M.Z. see PETERKIN, V.C.
KARLSSON, K.E., GRAHNEN, A., LEHR, T., STAAB, A., TILLMANN, C., MANDELBROT, L. see HIRT, D.
KARLSSON, M.O. & JONSSON, E.N. TROMMESHAUSER, D., RASCHIG, A., MANTEL-TEEUWISSE, A.K. see GUMBS,
Randomized exposure-controlled trials; SCHAEFER, H.G. & KLOFT, C. P.D.
impact of randomization and analysis Population pharmacokinetic modelling of MAO, P. see TANG, Y.-L.
strategies: 266 NS2330 (tesofensine) and its major MARBURY, T. see GUPTA, S.K.
KARLSSON, M.O. see FANTA, S. metabolite in patients with Alzheimer’s MARCUS, P. see FORST, T.
KARLSSON, M.O. see KARLSSON, K.E. disease: 36 MARIEN, K. see HOETELMANS, R.M.W.
KARLSSON, M.O. see LONNEBO, A. LEMENUEL-DIOT, A. see DARTOIS, C. MARTINEZ, C. see GUERRERO, J.A.
KARLSTAD, @. see SAKSHAUG, S. LENNARD, M.S. see DICKINSON, G.L. MATHIE, R.T. & FISHER, P. Homeopathy is
KAYE, J.A. see JICK, S.S. LEUNG, M. see PESCOVITZ, M.D. safe and does not lack positive evidence
KAYNAK, F. see UNVERIR, P. LEWIS, B.C. see ELLIOT, D.J. in clinical trials: 396
KEATING, M.J. see MOULD, D.R. LEWIS, L.D. see ARONSON, J.K. MAZOIT, J.-X. see BELOEIL, H.
KERN, S.E. see KANG, S.H. LEWIS, S. see MORTIMER, K.J. MCCORMICK, P.A. see DONNELLAN, F.
KIM, D.H. see KANG, S.H. LI, F-M. see TANG, Y.-L. MCFARLANE, L.C. see TAYAB, Z.R.
KIM, E.-Y. see KIM, H.-S. LI, Q. see XIN, H.-W. MCKAY, D. see PESCOVITZ, M.D.
KIM, H.-S., SUNWOO, Y.E., RYU, J-Y., LI, W. see TANG, Y.-L. MCLAY, J. see ROSS, S.
KANG, H.-J., JUNG, H.-E., SONG, LIN, N. see ZHANG, Y. MCLAY, J. see TOBAIQY, M.
I.-S., KIM, E.-Y., SHIM, J.-C., SHON, LINARES, O. see KANG, S.H. MCLAY, J.S. see STEWART, D.
J.-H. & SHIN, J.-G. The effect of LINNEBJERG, H., KOTHARE, P.A., PARK, MEHLOTRA, R.K., BOCKARIE, M.J. &
ABCG2 V12M, QI141K and Q126X, S., MACE, K., REDDY, S., MITCHELL, ZIMMERMAN, P.A. CYP2B6 983T>C
known functional variants in vitro, M. & LINS, R. Effect of renal polymorphism is prevalent in West Africa
on the disposition of impairment on the pharmacokinetics of but absent in Papua New Guinea:
lamivudine: 645 exenatide: 317 implications for HIV/AIDS treatment:
KIM, K.H. see CHOI, J.H. LINS, R. see LINNEBJERG, H. 391
KIM, K.M. see KANG, S.H. LIP, G.Y.H. & WATSON, T. Stroke MELTON, L. see PESCOVITZ, M.D.
KIST-VAN HOLTHE, J.E. see VAN DER prevention in atrial fibrillation — things MELVILLE, V. see DHAUN, N.
VORST, M.M.J. can only get better: 575 MENNING, L. see PETERKIN, V.C.
KLOFT, C. see LEHR, T. LIPWORTH, B.J. see TAYAB, Z.R. MENTRE, F. see DARTOIS, C.
KLUNGEL, O.H. see DOBRE, D. LISI, M. see GORI, T. METSARINNE, K. see TURPEINEN, M.
KLUNGEL, O.H. see GUMBS, P.D. LOCKHART, J. see HUGHES, J. MIETTUNEN, J. see TURPEINEN, M.
KLUNGEL, O.H. see SCHELLEMAN, H. LONG, A.J. see CUI, Y.M. MILANO, G. see MAGNE, N.
KOIVUVIITA, N. see TURPEINEN, M. LONNEBO, A., GRAHNEN, A. & MILEWSKA, A. see WYKRETOWICZ, A.
KOLZ, K. see GUPTA, S.K. KARLSSON, M.O. An integrated model MILTON, J.C. & ABDULLA, A. Prolonged
KORKMAZ, U. see CINEMRE, H. for the effect of budesonide on ACTH oro-facial dystonia in a 58 year old
KOTHARE, P.A. see LINNEBJERG, H. and cortisol in healthy volunteers: 125 female following therapy with bupropion
KRAHENBUHL, S. see HAEGELI, L. LOPEZ-SENDON, J.-L. see MORENO, R. and St John’s Wort: 717
KRAMER, W. see DHAUN, N. LOZANO, M.L. see GUERRERO, J.A. MINERS, J.O. see ELLIOT, D.J.
KRAUZE, T. see WYKRETOWICZ, A. LUNDGREN, S. see TURPEINEN, M. MIREMONT-SALAME, G. see
KRIBBEN, A. see STASS, H. LYLES, A. see BELL, J.S. ARIMONE, Y.
KUBITZA, D. see STASS, H. MISHRA, B. see SAHOO, S.
KUHLMANN, J. see MOULD, D.R. MA, Q. Development of oral anticoagulants: MISHRA, B., SADDICHHA, S., KUMAR,
KUMAR, R. see MISHRA, B. 263 R. & AKHTAR, S. Risperidone-induced
MACE, K. see LINNEBJERG, H. recurrent giant urticaria: 558
LACARELLE, B. see SOLAS, C. MACKAY, G.M. see FORREST, C.M. MISMETTI, P. see BERGES, A.
LAFFONT, C.M. see DARTOIS, C. MADIJAR, M. see GOLDSTEIN, L.H. MITCHELL, A. see STASS, H.
LAGUERRE, J. see CONIL, J.M. MAGNE, N., ETIENNE-GRIMALDI, M.-C., MITCHELL, M. see LINNEBJERG, H.
LAINE, K. see TURPEINEN, M. CALS, L., RENEE, N., FORMENTO, MITCHELL, P.B. see TANG, Y.-L.
LAMMERS, J.-W.J. see J.-L., FRANCOUAL, M. & MILANO, G. MOLIMARD, M. see ARIMONE, Y.
ESPOSITO-FESTEN, J.E. Dihydropyrimidine dehydrogenase MOLLER, J.-G. see STASS, H.
LANGLEY, R.W. see SAMUELS, E.R. activity and the [VS14+1G<A mutation in MONTASTRUC, J.L. see DURRIEU, G.
LAPORTE, S. see BERGES, A. patients developing SFU-related toxicity: MONTGOMERY, K. see NATH, C.E.
LAVEILLE, C. see DARTOIS, C. ast MOORE, N. see ARIMONE, Y.
LAVIT, M. see CONIL, J.M. MAHMUD, A. see OKECHUKWY, I. MORENO, R., FERNANDEZ, C.,
LE GUELLEC, C. see BENETON, M. MAHMUD, A., BENNETT, K., SANCHEZ-RECALE, A., CALVO, L.,
LEATHARD, H. see BECKWITH, S. OKECHUKWJU, I. & FEELY, J. National GALEOTE, G., SANCHEZ-AQUINO, R.
LECHAT, P. see ANTIGNAC, M. underuse of anti-thrombotic therapy in & LOPEZ-SENDON, J.-L. Risk of stent
838 64:6 Br J Clin Pharmacol
Author Index
thrombosis after sirolimus or paclitaxel Exposure-toxicity relationships for and does not lack positive evidence in
eluting coronary stent implantation: 110 tipifarnib in cancer patients: 219 clinical trials/Scottish GPs use of
MORTIMER, K.J., TATTERSFIELD, A.E., PESCOVITZ, M.D., VINCENTI, F., HART, Homeopathy: 398
TANG, Y., WU, K., LEWIS, S., M., MELTON, L., WHELCHEL, J., ROSTAMI-HODJEGAN, A. see
HOCHHAUS, G. & HARRISON, T.W. MULGAONKAR, S., MCKAY, D., DICKINSON, G.L.
Plasma concentrations of fluticasone LEUNG, M., CALLEJA, E. & BOUW, ROTH, W. see STANGIER, J.
propionate and budesonide following M.R. Pharmacokinetics, safety, and ROTHUIZEN, L.E. see TSCHUPPERT, Y.
inhalation: effect of induced efficacy of mycophenolate mofetil in ROUF, A. see STEWART, D.
bronchoconstriction: 439 combination with sirolimus or ROUGHEAD, E.E., PRATT, N. &
MOULD, D.R., BAUMANN, A., ciclosporin in renal transplant patients: GILBERT, A.L. Trends over 5 years in
KUHLMANN, J., KEATING, M.J., 758 cardiovascular medicine use in Australian
WEITMAN, S., HILLMEN, P., PETERKIN, V.C., BAUMAN, J.N., veterans with diabetes: 100
BRETTMAN, L.R., REIF, S. & GOOSEN, T.C., MENNING, L., MAN, RYU, J.Y. see KIM, H.-S.
BONATE, P.L. Population M.Z., PAULAUSKIS, J.D., WILLIAMS,
pharmacokinetics—pharmacodynamics of J.A. & MYRAND, S.P. Limited influence SADDICHHA, S. see MISHRA, B.
alemtuzumab (Campath©) in patients of UGTIA1*28 and no effect of SAHOO, S., MISHRA, B. & AKHTAR, S.
with chronic lymphocytic leukaemia UGT2B7*2 polymorphisms on UGTIA1 Dose-dependent acute excessive weight
and its link to treatment response: or UGT2B7 activities and protein gain and metabolic changes in a
278 expression in human liver microsomes: drug-naive patient on risperidone are
MULGAONKAR, S. see PESCOVITZ, M.D. 458 reversible with discontinuation: a case
MYRAND, S.P. see PETERKIN, V.C. PFISTERER, M. see HAEGELI, L. report: 715
PFUTZNER, A. see FORST, T. SAITO, M. see IWASHIMA, K.
NADERER, O.J. see ASARI, A. PILLAI, GC. & STEIMER, J.-L. SAIVIN, S. see CONIL, J.M.
NAKAGAML, T. see IWASHIMA, K. Commentary on Dartois et al. — model SAKSHAUG, S., FURU, K., KARLSTAD,
NARCISSO, B. see BENETON, M. building in population PK—PD analyses. @., RONNING, M. & SKURTVEIT, S.
NATH, C.E., SHAW, P.J., MONTGOMERY, A 2002-2004 literature survey: 578 Switching statins in Norway after new
K. & EARL, J.W. Population POIZOT-MARTIN, I. see SOLAS, C. reimbursement policy — a nationwide
pharmacokinetics of melphalan in POMP, E. see THUNELL, S. prescription study: 476
paediatric blood or marrow transplant PONS, G. see HIRT, D. SALEM, C.B. see HMOUDA, H.
recipients: 151 PONS, G. see JULLIEN, V. SALEM, C.B., HMOUDA, H. &
NAVARRO-NUNEZ, L. see POYNTON, MLR. see KANG, S.H. BOURAOUI, K. Glimepiride-induced
GUERRERO, J.A. PRASANNA, C.G. see SUBBANNA, P.K. vasculitis: a case report: 113
NOBLE, EDITED BY D. & TENDERA, M.., PRATT, N. see ROUGHEAD, E.E. SAMII, K. see CONIL, J.M.
NOBLE, D. Heart Rate Slowing by |; PRETI, A.P.M. see CIVELLI, M. SAMUELS, E.R., HOU, R.H., LANGLEY,
Current Inhibition: 400 PUHO, E. see BANHIDY, F. R.W., SZABADI, E. & BRADSHAW,
NOH, G.J. see KANG, S.H. C.M. Comparison of pramipexole with
QUARANTA, S. see SOLAS, C. and without domperidone
O’CONNOR, H. see TEELING, M. co-administration on alertness, autonomic,
OFORI, B., REY, E. & BERARD, A. Risk of RAIS, A. see JULLIEN, V. and endocrine functions in healthy
congenital anomalies in pregnant users of RANCHOR, A.V. see DOBRE, D. volunteers: 591
statin drugs: 496 RANE, A. see TURPEINEN, M. SANCHEZ-AQUINO, R. see MORENO, R.
OKECHUKWJU, I. see MAHMUD, A. RASCHIG, A. see LEHR, T. SANCHEZ-RECALE, A. see MORENO, R.
OKECHUKWU, I., MAHMUD, A., RATHGEN, K. see STANGIER, J. SANDERMAN, R. see DOBRE, D.
BENNETT, K. & FEELY, J. Choice of REDDY, S. see LINNEBJERG, H. SATO, Y. see IWASHIMA, K.
first antihypertensive — are existing REIF, S. see MOULD, D.R. SCHAEFER, H.G. see LEHR, T.
guidelines ignored?: 722 RENEE, N. see MAGNE, N. SCHAFERS, R.F. see STASS, H.
ONDER, E. see CINEMRE, H. REPONEN, P. see TURPEINEN, M. SCHELLEMAN, H., KLUNGEL, O.H.,
OTTO, V. see ASARI, A. REY, E. see HIRT, D. WITTEMAN, J.C.M., HOFMAN, A.,
OZDEMIR, V. see ZHANG, W. REY, E. see JULLIEN, V. VAN DUIJN, C.M., DE BOER, A. &
REY, E. see OFORI, B. STRICKER, B.H.CH. Pharmacogenetic
PAKRAVAN, N., BATEMAN], D.N. & RICHARDSON, W.N. & HENDERSON, L. interactions of three candidate gene
GODDARD, J. Effect of acute The safety of kava — a regulatory polymorphisms with ACE-inhibitors or
paracetamol overdose on changes in perspective: 418 B-blockers and the risk of atherosclerosis:
serum and urine electrolytes: 824 RITTER, J.M. see ARONSON, J.K. 57
PAN, A.X. see CUI, Y.M. RIVERA, J. see GUERRERO, J.A. SCHELLENS, J.H.M. see JOERGER, M.
PARK, K. see CHOI, J.H. ROCCA, H.P.B.-L. see HAEGELI, L. SCHUTTE, K. see FORST, T.
PARK, S. see LINNEBJERG, H. RON-AVRAHAM, G. see GOLDSTEIN, SCHWARTZ, S. see GUPTA, S.K.
PARKER, J.D. see GORI, T. Li. SEKAR, V. see HOETELMANS, R.M.W.
PAULAUSKIS, J.D. see PETERKIN, V.C. RONDELLI, I. see CIVELLI, M. SHAW, P.J. see NATH, C.E.
PEETERS, M. see HOETELMANS, R.M.W. RONNING, M. see SAKSHAUG, S. SHEN, Y. see XIN, H.-W.
PELKONEN, O. see TURPEINEN, M. ROSING, H. see JOERGER, M. SHIM, J.-C. see KIM, H.-S.
PENG, D.D. see ZHANG, W. ROSS, S. see TOBAIQY, M. SHIN, J.-G. see KIM, H.-S.
PEREZ-RUIXO, J.J., CHEN, W., ZHANG, ROSS, S., SIMPSON, C. & MCLAY, J. SHON, J.-H. see KIM, H.-S.
S., HAYES, S. & CHOW, A. Authors’ response: Homeopathy is safe SI, D. see ZHANG, Y.
Br J Clin Pharmacol
Author Index
SICURO, S. see GORI, T. SU, D. see XIN, H.-W. TSANTES, A. see BONOVAS, S.
SIEVENPIPER, J.L., EZATAGHA, A., SUBBANNA, P.K., PRASANNA, C.G. & TSCHUPPERT, Y., BUCLIN, T.,
DASCALU, A. & VUKSAN, V. When a GUNALE, B.K. Investigation on ROTHUIZEN, L.E., DECOSTERD, L.A.,
placebo is not a ‘placebo’: a placebo pharmacokinetics of mycophenolic acid in GALLEYRAND, J., GAUD, C. &
effect on postprandial glycaemia: 546 Chinese adult renal transplant patients: BIOLLAZ, J. Effect of dronedarone on
SIMON, N. see SOLAS, C. 245 renal function in healthy subjects: 785
SIMPSON, C. see ROSS, S. SUHARJONO, see ELLIOT, D.J. TUCKER, G.T. see DICKINSON, G.L.
SINCLAIR, S.R. see VAN DER SUNWOO, Y.E. see KIM, H.-S. TURPEINEN, M., KOIVUVIITA, N.,
SCHUEREN, B.J. SWAN, S. see DHAUN, N. TOLONEN, A., REPONEN, P.,
SINGH, N.K. Polonium-210 in news: an SWAN, S.K. see GUPTA, S.K. LUNDGREN, S., MIETTUNEN, J.,
allegory of a misappropriated science: SZABADI, E. see SAMUELS, E.R. METSARINNE, K., RANE, A.,
714 PELKONEN, O. & LAINE, K. Effect of
SITARAS, N.M. see BONOVAS, S. TANG, Y. see MORTIMER, K.J. renal impairment on the pharmacokinetics
SKURTVEIT, S. see BRAMNESS, J.G. TANG, Y.-L., MAO, P., LI, F.-M., LI, W., of bupropion and its metabolites: 165
SKURTVEIT, S. see SAKSHAUG, S. CHEN, Q., JIANG, F., CAI, Z.-J. &
SLIM, R. see HMOUDA, H. MITCHELL, P.B. Gender, age, smoking UNVERIR, P., TOPACOGLU, H.,
SMITH, T. see FORST, T. behaviour and plasma clozapine BOZKURT, S. & KAYNAK, F.
SMITH, W. see GUPTA, S.K. concentrations in 193 Chinese inpatients Cardiovascular toxicity due to metoprolol
SNAITH, A. see STEWART, D. with schizophrenia: 49 poisoning in a patient with coronary
SOLAS, C., SIMON, N., DROGOUL, M.-P., TANSEY, T. see CHURCH, R. artery disease: 694
QUARANTA, S., FRIXON-MARIN, V., TARRAL, A. see CIVELLI, M. UPTON, R.N. see FORNASINI, G.
BOURGAREL-REY, V., BRUNET, C., TATTERSFIELD, A.E. see MORTIMER, URIEN, S. see ANTIGNAC, M.
GASTAUT, J.-A., DURAND, A., K.J. URIEN, S. see HIRT, D.
LACARELLE, B. & POIZOT-MARTIN, TAYAB, Z.R., FARDON, T.C., LEE, D.K.C., URIEN, S. see JULLIEN, V.
I. Minimal effect of MDR1 and CYP3A5 HAGGART, K., MCFARLANE, L.C.,
genetic polymorphisms on the LIPWORTH, B.J. & HOCHHAUS, G. VAN DER HEIJDEN, A.J. see VAN DER
pharmacokinetics of indinavir in Pharmacokinetic/pharmacodynamic VORST, M.M.J.
HIV-infected patients: 353 evaluation of urinary cortisol suppression VAN DER MEER, Y.G. see HOELEN,
SONG, L.-S. see KIM, H.-S. after inhalation of fluticasone propionate D.W.M.
SOSTEK, M.B., CHEN, Y. & ANDERSSON, and mometasone furoate: 698 VAN DER SCHUEREN, B.J., DE HOON,
T. Effect of timing of dosing in relation to TEELING, M., O°CONNOR, H., FEELY, J. J.N., VANMOLKOT, F.H., VAN
food intake on the pharmacokinetics of & BENNETT, K. What therapies have HECKEN, A., DEPRE, M., KANE, S.A..,
esomeprazole: 386 replaced rofecoxib in Ireland?: 536 DE LEPELEIRE, I. & SINCLAIR, S.R.
SOUVEREIN, P.C. see GUMBS, P.D. TENDERA, M. see NOBLE, D. Reproducibility of the capsaicin-induced
SPECTOR, R.G. John Trounce: 116 TENG, C.H. see CUI, Y.M. dermal blood flow response as assessed
STAAB, A. see LEHR, T. THAKRAR, B.T., GRUNDSCHOBER, S.B. by laser Doppler perfusion imaging:
STAHLE, H. see STANGIER, J. & DOESSEGGER, L. Detecting signals 580
STANGIER, J., RATHGEN, K., STAHLE, of drug—drug interactions in a VAN DER VORST, M.M.J., KIST-VAN
H., GANSSER, D. & ROTH, W. The spontaneous reports database: 489 HOLTHE, J.E., DEN HARTIGH, J., VAN
pharmacokinetics, pharmacodynamics and THANACOODY, H.K.R. Thioridazine: DER HEIJDEN, A.J., COHEN, A.F. &
tolerability of dabigatran etexilate, a new resurrection as an antimicrobial agent?: BURGGRAAF, J. Absence of tolerance
oral direct thrombin inhibitor, in healthy 566 and toxicity to high-dose continuous
male subjects: 292 THEUMA, R. see FRENDO, M. intravenous furosemide in
STASS, H., BUHRMANN, S., MITCHELL, THEVENIN, A. see BELOEIL, H. haemodynamically unstable infants after
A., KUBITZA, D., MOLLER, J.-G., THUNELL, S., POMP, E. & BRUN, A. cardiac surgery: 796
KRIBBEN, A., WENZEL, R.R. & Guide to drug porphyrogenicity prediction VAN DER WIEL, H.E. see HARMARK, L.
SCHAFERS, R.F. The influence of and drug prescription in the acute VAN DUIJN, C.M. see SCHELLEMAN, H.
continuous venovenous haemodialysis on porphyrias: 668 VAN GROOTHEEST, A.C. see
the pharmacokinetics of multiple oral TIDDENS, H.A.W.M. see HARMARK, L.
moxifloxacin administration to patients ESPOSITO-FESTEN, J.E. VAN HECKEN, A. see VAN DER
with severe renal dysfunction: 745 TILLMANN, C. see LEHR, T. SCHUEREN, B.J.
STAVROS, F. see DHAUN, N. TJAN, D.H.T. see HOELEN, D.W.M. VAN PUIJENBROEK, E.P. see DE GROOT,
STEIMER, J.-L. see (COLIN) PILLAI, G. TOBAIQY, M., MCLAY, J. & ROSS, S. M.C.H.
STEWART, D., ROUF, A., SNAITH, A., Foundation year | doctors and clinical VAN SONDEREN, E. see DOBRE, D.
ELLIOTT, K., HELMS, P.J. & MCLAY, pharmacology and therapeutics teaching. VAN VELDHUISEN, D.J. see DOBRE, D.
J.S. Attitudes and experiences of A retrospective view in light of VAN VUGT, R. see HOELEN, D.W.M.
community pharmacists towards experience: 363 VAN ZANTEN, A.R.H. see HOELEN,
paediatric off-label prescribing: a TOLONEN, A. see TURPEINEN, M. D.W.M.
prospective survey: 90 TOPACOGLU, H. see UNVERIR, P. VANMOLKOT, F.H. see VAN DER
STOLFO, G.D. see GORI, T. TRANCHAND, B. see BERGES, A. SCHUEREN, B.J.
STONE, T.W. see FORREST, C.M. TRANCHAND, B. see DARTOIS, C. VERMORKEN, J.B. see JOERGER, M.
STOY, N. see FORREST, C.M. TRELUYER, J.M. see JULLIEN, V. VERSCHUREN, W.M.M. see GUMBS, P.D.
STRICKER, B.H.CH. see TRELUYER, J.-M. see HIRT, D. VEYRAC, G. see VICTORRI-VIGNEAU, C.
SCHELLEMAN, H. TROMMESHAUSER, D. see LEHR, T. VICENTE, V. see GUERRERO, J.A.
840 64:6 Br J Clin Pharmacol
Author Index |
VICTORRI-VIGNEAU, C., DAILLY, E., WILLEMSE, P.H.B. see JOERGER, M. YU, A.-R. see XIN, H.-W.
VEYRAC, G. & JOLLIET, P. Evidence WILLIAMS, J.A. see PETERKIN, V.C. YUEN, E. see CUI, Y.M.
of zolpidem abuse and dependence: WILSON, A.D. see HOWELL, C. YUEN, G.J. see ASARI, A.
results of the French Centre for WISE, S.D. see CUI, Y.M.
Evaluation and Information on WITTEMAN, J.C.M. see SCHELLEMAN, H. ZANEN, P. see ESPOSITO-FESTEN, J.E.
Pharmacodependence (CEIP) network WOODFALL, B. see HOETELMANS, ZHANG, S. see PEREZ-RUIXO, J.J.
survey: 198 R.M.W. ZHANG, W., CHEN, B.-L., OZDEMIR, V.,
VINCENTI, F. see PESCOVITZ, M.D. WU, K. see MORTIMER, K.J. HE, Y.-J., ZHOU, G., PENG, D.D..,
VISSER, S.T. see ATTHOBARI, J. WU, X.-C. see XIN, H.-W. DENG, S., XIE, Q.-Y., XIE, W., XU,
VUKSAN, V. see SIEVENPIPER, J.L. WYKRETOWICZ, A., GUZIK, P., L.-Y., WANG, L.-C., FAN, L., WANG, A.
KRAUZE, T., ADAMSKA, K.., & ZHOU, H.-H. SLCO/BI] 521T-C
WALLER, D.G. Drugs and the kidney: more MILEWSKA, A. & WYSOCKI, H. functional genetic polymorphism and
than a question of dose: 719 Add-on therapy with doxazosin in lipid-lowering efficacy of multiple-dose
WALLER, D.G. Off-label and unlicensed patients with hypertension influences pravastatin in Chinese coronary heart
prescribing for children: have we made arterial stiffness and albuterol-mediated disease patients: 346
any progress?: | arterial vasodilation: 792 ZHANG, Y., SI, D., CHEN, X., LIN, N.,
WANG, A. see ZHANG, W. WYSOCKI, H. see WYKRETOWICZ, A. GUO, Y., ZHOU, H. & ZHONG, D.
WANG, L.-C. see ZHANG, W. Influence of CYP2C9 and CYP2C19
WANG, Z. see GUPTA, S.K. XIE, Q.-Y. see ZHANG, W. genetic polymorphisms on
WARING, W.S. see HOWELL, C. XIE, W. see ZHANG, W. pharmacokinetics of gliclazide MR in
WATSON, T. see LIP, G.Y.H. XIN, H.-W., WU, X.-C., LI, Q., YU, A.-R., Chinese subjects: 67
WEBB, D.J. see DEAR, J.W. ZHU, M., SHEN, Y., SU, D. & XIONG, ZHAO, X. see CUI, Y.M.
WEBB, D.J. see DHAUN, N. L. Effects of Schisandra sphenanthera ZHONG, D. see ZHANG, Y.
WEITMAN, S. see MOULD, D.R. extract on the pharmacokinetics of ZHOU, G. see ZHANG, W.
WENK, M. see HAEGELI, L. tacrolimus in healthy volunteers: 469 ZHOU, H. see ZHANG, Y.
WENZEL, R.R. see STASS, H. XIONG, L. see XIN, H.-W. ZHOU, H.-H. see ZHANG, W.
WHELCHEL, J. see PESCOVITZ, M.D. XU, L.-Y. see ZHANG, W. ZHOU, Y. see CUI, Y.M.
WIART, C. & HOUGHTON, P. ZHU, M. see XIN, H.-W.
Ethnopharmacology of Medicinal Plants: YASUI-FURUKORI, N. see IWASHIMA, K. ZIMMERMAN, P.A. see MEHLOTRA, R.K.
Asia and the Pacific: 248 YEO, K.P. see CUI, Y.M. ZUFFEREY, P. see BERGES, A.
Br J Clin Pharmacol 64:6
British Journal of Clinical Pharmacology 11/j.1365-2125.2007.03075.x
SUBJECT INDEX
This index was compiled from the keywords
3TC, 738 CHF 4227, 304 dose-effect, 686
5-amino levulinate synthase, 668 children, 105, 151, 241 doxazosin, 792
5-fluorouracil, 613 Chinese, 445 dronedarone, 785
ABCG2, 645 Chinese race, 49 drug costs, 476
absorption, 804 ciclosporin, 758 drug development, 566
ACE inhibitors, 100, 792 ciclosporin (cyclosporine A), 772 drug effectiveness, 406
ACTH, 125 circadian variation, 125 drug interactions, 373
activated partial thromboplastin time, 292 cirrhosis, 550 drug metabolism, 14
active metabolite, 36 clindamycin, 542 drug monitoring, 428, 613
acute coronary syndrome, 694 clinical pharmacokinetics, 67 drug overdose, 192
acute interstitial nephritis, 819 clinical pharmacology and therapeutics, 363 drug resistance, 566
acute myocardial infarction, 662 clinical trial simulation, 14, 266 drug safety, 622
adherence to regulations, 476 clozapine, 49 drug therapy, 668
adrenergic vasoconstriction, 421 community pharmacy, 90 drug use, 810
adverse drug reactions, 542, 233, 482, 819 congenital anomalies, 496 drug utilisation, 100
aerosols, 241 consumer, 527 drug—drug interactions, 489
alertness, 591 continual reassessment method, 686 dysgeusia, 542
Alzheimer’s disease, 36 continuous intravenous furosemide, 796
analgesic therapy, 75 co-prescription, 536 ecarin clotting time, 292
antihypertensive, 381 cord plasma concentrations, 634 efavirenz, 391
antihypertensive drugs, 57 coronary heart disease, 346 elderly, 428
antihypertensives, 722 cortisol, 125 electrocardiograph, 192
antilipademic agents, 496 COX-2 inhibitors, 536 electroencephalographic approximate entropy,
antimicrobial, 566 COX- inhibitors, 824 3
antiplatelet, 100 creatinine clearance, 785 endothelial dysfunction, 792
antiretroviral drugs, 391 cyclo-oxygenase (COX), 824 endothelin, 733
antithrombotic therapy, 706 CYP2B6, 391 endothelium, 145
arrhythmia, 192 CYP2C18, 450 end-stage renal disease, 317
arterial stiffness, 792 CYP2C19, 67, 450 enoxaparin, 428
arthritis, 517 CYP2C9, 450 ergotamine, 510
asthma, 241, 328, 439 CYP2C9, 67 esomeprazole capsules, 386
atherosclerosis, 57 CYP2D6, 96, 445 ESRD, 738
atomoxetine, 445 CYP2D6* 10, 445 exenatide, 31 ~
/
atrial fibrillation, 706 CYP3A4, 772 exposure-response, 278
attitudes, 90 CYP3A5
axon reflex, 421 cytochrome P-450 enzyme system, 668 flavonoid, 133
cytochrome P450, 14, 165, 450 fluoropyrimidine, 237
B-blocker poisoning, 694 cytokines, 517 fluticasone propionate, 698
bibliometry, 603 food—-drug interactions, 386
bupropion, 165 dabigatran etexilate, 292 foundation programme doctors, 363
burn patients, 27 dabigatran, 292 fractional excretion of electrolytes, 824
darkness reflex, 591 functional polymorphism, 346
calcitonin gene-related peptide, 580 darunavir, 655 furosemide, 804
calcium antagonists, 83 desensitization, 421
CAM, 546 desloratadine, 174 gastro-oesophageal reflux disease, 83
cancer patients, 219 developmental, 772 ender, 49
capsaicin, 580 diabetes, 100 o ne polymorphism, 237
cardiac surgery, 796 diabetes, 546 09g9 9yo o O neral population, 810
cardio-renal, 810 diclofenac, 662 oO neric, 680
cardiotoxicity, 192 dietary supplements, 373 zenotype, 96
cardiovascular, 100 digoxin, 706 zinseng, 546
997299
carisoprodol, 210 dihydropyrimidine dehydrogenase, 237 q1 9 = Qo N a oO oO ~~ rN SD
causality assessment, 482 direct thrombin inhibitor, 292 glucose, 546
ceftazidime, 27 domperidone, 591 glypressin, 550
chemoprevention, 255 dose, 174 guidelines, 722
Br J Clin Pharmacol 64:6 842-844 842 © 2007 Blackwell Publishing Ltd
Subject Index
haematological malignancy, 255 nefopam, 686 population pharmacokinetics, 151, 27, 750,
haemodialysis, 335 nelfinavir, 634 772
healthy volunteers, 469 neopterin, 517 population
heart failure, 406 nephrotoxicity, 824 pharmacokinetics-pharmacodynamics,
HEK 293T cells, 133 neural network model, 3 125
herbal medicine, 373 NMDA receptor antagonist, 75 porphyrias, 668
herb-drug interactions, 373 noncardiac chest pain, 83 porphyrinogenicity, 668
HIV, 105, 634 nonlinear mixed effect model, 603 porphyrogenicity, 668
HPA axis, 125 nonlinear pharmacokinetics, 278 postprandial, 546
human liver microsomes, 458 NONMEM, 36, 151, 278, 428, 634 pramipexole, 591
non-steroidal anti-inflammatory drugs pravastatin efficacy, 346
in silico, 14 (NSAIDs), 824 pregnancy registry, 496
incretin mimetic, 317 noradrenaline, 421 pregnancy, 496, 510
indinavir, 353 North America, 391 prescribing, 363, 381, 722
indirect response model, 278 Norway, 476 prescription database, 476
infants, 796 NS2330, 36 prescription drug abuse, 210
inhaled corticosteroid, 439 NSAIDs, 536, 662 preterm birth, 510
inpatients, 373 proton pump inhibitors, 536, 819
interaction, 655 observational studies, 406 pulmonary deposition, 698
interethnic variation, 346 observational study, 662 pupil, 591
interferon alfa-2b, 726 off-label prescribing, 90
internal medicine, 373 ordinary sigmoid E,,,, model, 3 QT prolongation, 566
intrauterine growth retardation, 510 organic cation transport, 785 questionnaire, 90, 363
ischaemia, 145
ischaemic complications, 550 paclitaxel, 622 randomized concentration-controlled trial,
paediatric, 174, 772 266
Japanese, 96 paediatrics, 90 randomized dose-controlled trial, 266
painful neuropathy, 75 reaction phenotyping, 450
kidney, 750 Papua New Guinea, 391 remifentanil, 3
kynurenine, 517 paracetamol, 824 renal failure, 165
patient safety, 363 renal impairment, 317, 733
lamivudine, 645, 738 patient-related variables, 49 renal insufficiency, 726
L-carnitine, 335 pegylation, 726 renal transplant, 758
LDL cholesterol, 304 peritoneal dialysis, 738 renal transplantation, 772
light reflex, 591 personality, 96 reperfusion, 145
lipid lowering therapy, 100 P-glycoprotein, 353 reproducibility, 580
liver impairment, 622 pharmacist, 527 risk, 233
logistic regression, 278 pharmacodependence, 198 ritonavir, 655
low birth weight, 510 pharmacodynamic, 603 rofecoxib, 536
low-molecular-weight heparin, 428 pharmacodynamics, 292, 804
pharmacoepidemiological, 706 safety monitoring, 192
markers of bone metabolism, 304 pharmacoepidemiology, 210, 476 safety, 174
MDRI, 185 pharmacogenetic variation, 346 salbutamol, 241
MDRI, 353 pharmacogenetics, 14, 57, 237 savings, 680
measure of interaction, 489 pharmacogenetics, 57 Schisandra sphenanthera extract, 469
medical students, 233 pharmacokinetic, 428, 603, 733 schizophrenia, 49
medicalization, 810 pharmacokinetics, 105, 165, 174, 185, screening, 810
melatonin, 517 SERM, 304
melphalan, 151 469, 613, 622, 645, 726, 738, 745, 758, severe renal dysfunction, 745
meprobamate, 210 804 sex, 36
meta-analysis, 255 pharmacology, 439 single and multiple dose trial, 304
metoprolol poisoning, 694 pharmacometrics, 266 single nucleotide polymorphism, 353
migraine therapy, 580 pharmacovigilance, 233, 542 sirolimus, 758
model building, 603 placebo effect, 546 sitaxsentan, 733
model validation, 278 placental transfer, 634 SLCOIB1, 346
model-based analysis, 266 plasma levels, 49 smooth muscle cells, 133
modelling and simulation, 14 plasma protein binding, 698 social pharmacology, 233
modelling, platelets, 133 spontaneous reporting, 819
mometasone furoate, 698 poisoning, 192 statins, 255, 476, 496, 680
monodisperse aerosols, 328 polymorphism, 67, 185, 458, 645 stavudine, 105
Moxifloxacin, 745 polymorphisms, 57 steroids, 328
multiplicative and additive models, 489 population analysis, 622 study design, 266
muscle, 335 population model, 603 sublingual administration, 804
mycophenolate mofetil, 758 population pharmacokinetic modelling, 36 survey, 90
Br J Clin Pharmacol 64:6 843
| Subject Index
sympathetic nervous system, 421 TP signaling, 133 vasodilation, 580
systemic side-effects, 698 transplantation, 750 venovenous haemodialysis, 745
trials, 381 Vietnamese, 527
tacrolimus, 185, 469, 750 tryptophan, 517
taste disorder, 542 tuberculosis, 566 West Africa, 391
tenofovir disoproxil fumarate, 655 Type 2 diabetes, 317 written medicine information, 527
thioridazine, 566
tipifarnib, 219 UDP-glucuronosyltransferases, 458 Zeffix™, 738
TMC114, 655 UGTIA1*28, 458 zolpidem, 198
tolerance, 796 UGT2B7*2, 458
toxicity, 219, 237, 796
64:6 Br J Clin Pharmacol